Pathogenesis and clinical management of arboviral diseases

doi:10.5501/wjv.v14.i1.100489

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1815)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-6) series.

Item

Count

PDF

HTML

1166

Figures (1-1)

Tables (1-6)

104

Sum=1407

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

154

Sum=234

Publishing Process of This Article

Item

Count

Browse

Download

Sum=98

Mar 25, 2025 (publication date) through Jan 24, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Virology

ISSN

2220-3249

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Virol. Mar 25, 2025; 14(1): 100489
Published online Mar 25, 2025. doi: 10.5501/wjv.v14.i1.100489

Table 3 Zika vaccines currently in clinical trials-clinicalTrials.gov database

Vaccine technology platforms	Intervention/treatment	ClinicalTrials.gov ID	Phase	Status	Sponsor
DNA vaccine	Biological: VRC-ZKADNA090-00-VP; Other: VRC-PBSPLA043-00-VP	NCT03110770	2	Completed	NIAID
	Biological: VRC-ZKADNA090-00-VP	NCT02996461	1	Completed	NIAID
	Biological: VRC-ZKADNA085-00-VP	NCT02840487	1	Completed	NIAID
mRNA vaccine	Placebo/biological: mRNA-1325	NCT03014089	1	Completed	ModernaTX, Inc.
	Placebo/biological: mRNA-1893	NCT04064905	1	Completed	ModernaTX, Inc.
	Placebo/biological: mRNA-1893	NCT04917861	2	Active, Not Recruiting	ModernaTX, Inc.
Viral vectored vaccine	Placebo/biological: MV-ZIKA-RSP vaccinations (high or low doses)	NCT04033068	1	Completed	Themis Bioscience GmbH
	Biological: ChAdOx1 Zika	NCT04015648	1	Completed	University of Oxford
	Placebo/biological: MV-ZIKA	NCT02996890	1	Completed	Themis Bioscience GmbH
Live attenuated vaccine	Placebo/biological: rZIKV/D4Δ30-713	NCT03611946	1	Completed	NIAID
Purified inactivated vaccine	Placebo/biological: VLA1601	NCT03425149	1	Completed	Valneva Austria GmbH
	Placebo/biological: Zika virus purified inactivated vaccine	NCT02937233	1	Completed	Kathryn Stephenson
	Biological: VLA1601/CpG 1018^®/3M-052-AF	NCT06334393	1	Recruiting	Valneva Austria GmbH
	Placebo/biological: PIZV	NCT03343626	1	Completed	Takeda
	Placebo/biological: Zika virus purified inactivated vaccine	NCT03008122	1	Completed	NIAID
	Placebo/biological: IXIARO; YF Vax 17D strain and Zika virus purified inactivated vaccine	NCT02963909	1	Completed	NIAID
	Drug: Saline/biological: Zika virus purified inactivated vaccine	NCT02952833	1	Completed	NIAID

NIAID: National Institute of Allergy and Infectious Diseases.

Citation: Cenci Dietrich V, Costa JMC, Oliveira MMGL, Aguiar CEO, Silva LGO, Luz MS, Lemos FFB, de Melo FF. Pathogenesis and clinical management of arboviral diseases. World J Virol 2025; 14(1): 100489
URL: https://www.wjgnet.com/2220-3249/full/v14/i1/100489.htm
DOI: https://dx.doi.org/10.5501/wjv.v14.i1.100489